Catalyst Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Catalyst Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CPRX

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. 

CEO
Richard John Daly
CEORichard John Daly
Employees
182
Employees182
Headquarters
Coral Gables, Florida
HeadquartersCoral Gables, Florida
Founded
2002
Founded2002
Employees
182
Employees182

CPRX Key Statistics

Market cap
3.85B
Market cap3.85B
Price-Earnings ratio
18.08
Price-Earnings ratio18.08
Dividend yield
Dividend yield
Average volume
2.40M
Average volume2.40M
High today
$31.46
High today$31.46
Low today
$30.70
Low today$30.70
Open price
$31.44
Open price$31.44
Volume
4.73M
Volume4.73M
52 Week high
$32.56
52 Week high$32.56
52 Week low
$19.05
52 Week low$19.05

Stock Snapshot

The current Catalyst Pharmaceuticals(CPRX) stock price is $31.43, with a market capitalization of 3.85B. The stock trades at a price-to-earnings (P/E) ratio of 18.08.

As of 2026-07-01, Catalyst Pharmaceuticals(CPRX) stock has fluctuated between $30.70 and $31.46. The current price stands at $31.43, placing the stock +2.4% above today's low and -0.1% off the high.

The Catalyst Pharmaceuticals(CPRX)'s current trading volume is 4.73M, compared to an average daily volume of 2.4M.

During the past year, Catalyst Pharmaceuticals(CPRX) stock moved between $19.05 at its lowest and $32.56 at its peak.

During the past year, Catalyst Pharmaceuticals(CPRX) stock moved between $19.05 at its lowest and $32.56 at its peak.

CPRX News

TipRanks 9h
Catalyst Pharma reports positive Phase 1 AGAMREE results

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Investing.com 17h
Catalyst reports Phase 1 vamorolone study results - Investing.com

...

Catalyst reports Phase 1 vamorolone study results - Investing.com
Simply Wall St 5d
Catalyst Pharmaceuticals Following Strong Rare Disease Results Is The Upside Already Priced In

Catalyst Pharmaceuticals (CPRX) has drawn investor attention after its rare-disease portfolio produced annual revenue of $596.958 million and net income of $221...

Catalyst Pharmaceuticals Following Strong Rare Disease Results Is The Upside Already Priced In

People also own

Based on the portfolios of people who own CPRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.